MapLight Therapeutics IPO Pricing Announcement
MapLight Therapeutics, Inc., a biopharmaceutical company committed to enhancing the lives of those struggling with severe central nervous system disorders, has revealed the pricing details for its initial public offering (IPO). The company plans to offer 14,750,000 shares of common stock at a starting price of $17.00 per share. Additionally, it has provided underwriters a 30-day option to buy up to 2,212,500 more shares at the same offering price, minus any applicable underwriting discounts and commissions.
Concurrent Private Placement Details
Alongside the IPO, MapLight will also conduct a concurrent private placement. This entails the sale of 476,707 shares of common stock at the IPO price to affiliates of Goldman Sachs & Co. LLC. However, shares sold in this private placement will not be registered under the Securities Act of 1933. The anticipated gross proceeds from both the IPO and the private placement are projected to reach $258.9 million, before accounting for the underwriters' options.
Trading and Offering Expectations
The initiation of trading for the shares on the Nasdaq Global Market is expected to begin shortly, scheduled for October 27. The shares will trade under the symbol "MPLT". The company expects to finalize the offering by October 28, pending the completion of standard closing conditions.
Role of Managing Underwriters
For this offering, Morgan Stanley, Jefferies, Leerink Partners, and Stifel are serving as joint book-running managers. Their experienced roles in guiding this IPO underline the strategic importance of this event for MapLight Therapeutics.
Company Background and Product Candidates
MapLight Therapeutics focuses on providing innovative solutions for patients experiencing debilitating conditions related to the central nervous system. Founded by leading figures in psychiatry and neuroscience, the company aims to develop circuit-specific pharmacotherapies that are currently scarce. The flagship product candidate, ML-007C-MA, is a combination of an investigational M1/M4 muscarinic agonist and a peripheral anticholinergic, which is now undergoing Phase 2 clinical trials to target schizophrenia and Alzheimer's disease psychosis.
Investor Relations and Further Information
All relevant registration documentation for these securities has been filed with the U.S. Securities and Exchange Commission. This filing became automatically effective as of October 25. Interested parties can access the final prospectus for detailed information once it is available.
Should investors wish to follow up or gather more insights, they can reach out to the investor relations team via email at investors@maplightrx.com. Media inquiries can be directed to media@maplightrx.com.
Frequently Asked Questions
What is the price of MapLight's IPO?
The initial public offering price is set at $17.00 per share.
When does trading begin for MapLight Therapeutics?
Trading is expected to start on October 27 on the Nasdaq Global Market.
How many shares is MapLight offering in its IPO?
MapLight is offering a total of 14,750,000 shares in the IPO.
Who are the underwriters for this offering?
Morgan Stanley, Jefferies, Leerink Partners, and Stifel are the joint book-running managers for the IPO.
What is MapLight's primary focus?
MapLight Therapeutics aims to develop therapies for patients suffering from severe central nervous system disorders.
